相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Chemical screen identifies shikonin as a broad DNA damage response inhibitor that enhances chemotherapy through inhibiting ATM and ATR
Fangfang Wang et al.
ACTA PHARMACEUTICA SINICA B (2022)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Shikonin-mediated PD-L1 degradation suppresses immune evasion in pancreatic cancer by inhibiting NF-KB/STAT3 and NF-KB/CSN5 signaling pathways
Zhiyan Ruan et al.
PANCREATOLOGY (2021)
Shikonin and 4-hydroxytamoxifen synergistically inhibit the proliferation of breast cancer cells through activating apoptosis signaling pathway in vitro and in vivo
Hong-Yan Lin et al.
CHINESE MEDICINE (2020)
Pyruvate Kinase M2 is a marker of poor prognosis in lung adenocarcinoma but not lung squamous cell carcinoma
Junxia Zhang et al.
Translational Cancer Research (2020)
Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors
Zhenming Jin et al.
NATURE (2020)
Nucleus-located PDK1 regulates growth, invasion and migration of breast cancer cells
Delu Gan et al.
LIFE SCIENCES (2020)
Phosphorylation of PDHA by AMPK Drives TCA Cycle to Promote Cancer Metastasis
Zhen Cai et al.
MOLECULAR CELL (2020)
Hemistepsin A suppresses colorectal cancer growth through inhibiting pyruvate dehydrogenase kinase activity
Ling Jin et al.
SCIENTIFIC REPORTS (2020)
Microenvironmental control of glucose metabolism in tumors by regulation of pyruvate dehydrogenase
Tereza Golias et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies
Yi-Zhou Jiang et al.
CANCER CELL (2019)
Prolactin modulates TNBC aggressive phenotype limiting tumorigenesis
Vanessa M. Lopez-Ozuna et al.
ENDOCRINE-RELATED CANCER (2019)
Design and characterization of α-lipoic acyl shikonin ester twin drugs as tubulin and PDK1 dual inhibitors
Hong-Yan Lin et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Shikonin enhances sensitization of gefitinib against wild-type EGFR non-small cell lung cancer via inhibition PKM2/stat3/cyclinD1 signal pathway
Jian-cai Tang et al.
LIFE SCIENCES (2018)
Identification of Novel Pyruvate Dehydrogenase Kinase 1 (PDK1) Inhibitors by Kinase Activity-Based High-Throughput Screening for Anticancer Therapeutics
Wen Zhang et al.
ACS COMBINATORIAL SCIENCE (2018)
PDK1 promotes tumor cell proliferation and migration by enhancing the Warburg effect in non-small cell lung cancer
Tao Liu et al.
ONCOLOGY REPORTS (2017)
Therapeutic Targeting of the Pyruvate Dehydrogenase Complex/Pyruvate Dehydrogenase Kinase (PDC/PDK) Axis in Cancer
Peter W. Stacpoole
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Therapeutic Targeting of the Pyruvate Dehydrogenase Complex/Pyruvate Dehydrogenase Kinase (PDC/PDK) Axis in Cancer
Peter W. Stacpoole
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Fundamentals of cancer metabolism
Ralph J. DeBerardinis et al.
SCIENCE ADVANCES (2016)
Synthesis of aryl dihydrothiazol acyl shikonin ester derivatives as anticancer agents through microtubule stabilization
Hong-Yan Lin et al.
BIOCHEMICAL PHARMACOLOGY (2015)
JX06 Selectively Inhibits Pyruvate Dehydrogenase Kinase PDK1 by a Covalent Cysteine Modification
Wenyi Sun et al.
CANCER RESEARCH (2015)
Differences in Metabolic Programming Define the Site of Breast Cancer Cell Metastasis
Heike Doeppler et al.
CELL METABOLISM (2015)
PDK1-Dependent Metabolic Reprogramming Dictates Metastatic Potential in Breast Cancer
Fanny Dupuy et al.
CELL METABOLISM (2015)
Targeting Tumor Metabolism for Cancer Treatment: Is Pyruvate Dehydrogenase Kinases (PDKs) a Viable Anticancer Target?
Wen Zhang et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2015)
Global gene expression analysis of tamoxifen-resistant breast cancer cell lines identified a gene signature predictive of clinical outcome of breast cancer patients treated with endocrine therapy
Daniel Elias Roro et al.
CANCER RESEARCH (2014)
Traditional Chinese Medicine Remedy to Jury: The Pharmacological Basis for the Use of Shikonin as an Anticancer Therapy
I. Andujar et al.
CURRENT MEDICINAL CHEMISTRY (2013)
Expression of pyruvate dehydrogenase kinase-1 in gastric cancer as a potential therapeutic target
Hoon Hur et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2013)
Cancer drug resistance: an evolving paradigm
Caitriona Holohan et al.
NATURE REVIEWS CANCER (2013)
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Brian D. Lehmann et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
A novel antiestrogen agent Shikonin inhibits estrogen-dependent gene transcription in human breast cancer cells
Yuan Yao et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Metabolic Modulation of Glioblastoma with Dichloroacetate
E. D. Michelakis et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
Naturally-occurring shikonin analogues - A class of necroptotic inducers that circumvent cancer drug resistance
Yanyan Xuan et al.
CANCER LETTERS (2009)
Distinct structural mechanisms for inhibition of pyruvate dehydrogenase kinase isoforms by AZD7545, dichloroacetate, and radicicol
Masato Kato et al.
STRUCTURE (2007)
Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt
R. B. Robey et al.
ONCOGENE (2006)
Lactate in solid malignant tumors: Potential basis of a metabolic classification in clinical oncology
S Walenta et al.
CURRENT MEDICINAL CHEMISTRY (2004)
分享论文
